Gritstone Bio Basic EPS 2017-2024 | GRTSQ
Gritstone Bio basic eps from 2017 to 2024. Basic eps can be defined as a company's net earnings or losses attributable to common shareholders per basic share basis.
Gritstone Bio Annual Basic EPS |
2023 |
$-1.20 |
2022 |
$-1.32 |
2021 |
$-0.95 |
2020 |
$-2.79 |
2019 |
$-2.81 |
2018 |
$-7.26 |
2017 |
$-20.70 |
2016 |
$-11.21 |
Gritstone Bio Quarterly Basic EPS |
2024-06-30 |
$-0.16 |
2024-03-31 |
$-0.34 |
2023-12-31 |
$-0.26 |
2023-09-30 |
$-0.33 |
2023-06-30 |
$-0.31 |
2023-03-31 |
$-0.30 |
2022-12-31 |
$-0.29 |
2022-09-30 |
$-0.35 |
2022-06-30 |
$-0.34 |
2022-03-31 |
$-0.34 |
2021-12-31 |
$-0.36 |
2021-09-30 |
$-0.36 |
2021-06-30 |
$-0.33 |
2021-03-31 |
$0.10 |
2020-12-31 |
$-0.70 |
2020-09-30 |
$-0.69 |
2020-06-30 |
$-0.69 |
2020-03-31 |
$-0.71 |
2019-12-31 |
$-0.79 |
2019-09-30 |
$-0.77 |
2019-06-30 |
$-0.63 |
2019-03-31 |
$-0.62 |
2018-12-31 |
$12.94 |
2018-09-30 |
$-7.60 |
2018-06-30 |
$-6.57 |
2018-03-31 |
$-6.03 |
2017-12-31 |
|
2017-09-30 |
$-4.59 |
2016-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|